You are here

Bioiberica approves its combined drug for osteoarthritis in five more European countries

24 Apr 2018
Healthcare
  • The drug agencies of France, Austria, Hungary, Poland, and Finland have authorised it as an ethical drug
  • The medication is composed of chondroitin sulphate and glucosamine hydrochloride for the symptomatic treatment of knee osteoarthritis
  • With these new approvals, Bioibérica’s pushes forward in its international expansion plan in the joint health and mobility areas

Bioiberica's combination of chondroitin sulphate and glucosamine hydrochloride, a slow action drug to treat osteoarthritis symptoms, was approved as an ethical drug in France, Austria, Hungary, Poland, and Finland through a mutual recognition process from Spain.

This approval confirms that Drug Agencies from different countries attest to the effectiveness and safety of the combination of pharmaceutical grade chondroitin sulphate and glucosamine hydrochloride. This drug has proven to reduce pain and improve mobility in people affected by knee osteoarthritis which, due to its safety profile, could also be used as an alternative by those patients with cardiovascular or gastrointestinal problems who should not be prescribed anti-inflammatory drugs chronically’, stated Dr Juan Gispert, Bioiberica's R&D director.

The principle study that guarantees its effectiveness is the MOVES clinical trial, published in the Annals of the Rheumatic Diseases[1], which concludes that the combination of chondroitin sulphate and glucosamine has an effectiveness comparable to the anti-inflammatory drug celecoxib after six months of treatment in patients with osteoarthritis and moderate to severe pain. It was observed that the combination of these two drugs relieves pain in a clinically relevant way. It also improves functional capacity, stiffness, relieves inflammation and joint effusion.

With these new approvals, a total of six European countries have approved Bioiberica brand’s combination of chondroitin sulphate and glucosamine hydrochloride. This year, the company plans to sign licensing and distribution agreements with companies specialised in the osteoarticular field to launch the product in the five countries where the drug was recently approved.

Bioiberica is the first European producer of chondroitin sulfate and international leader in joint health and chondroprotection thanks to a constant dedication and commitment to science and research. Vertically integrated, from the active ingredient to the finished product, Bioiberica offers its customers all their medical, scientific and commercial knowledge for the joint development of the market.


[1] Hochberg MC, et al. Combined chondroitin sulphate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis. 2016 Jan;75(1):37-44.

Related News

29 May 2022
Healthcare

With World Digestive Health Day around, shortly followed by World Allergy Awareness Week (5-11 June), we’re exploring the increasing relevance of a relatively unknown digestive health disorder – histamine intolerance.

25 May 2022
Healthcare

New pre-clinical study showed that Dermial® hyaluronic acid matrix ingredient increased type I collagen production by almost half – an observation not seen with standard hyaluronic acid from fermentation or extraction origin.

17 Apr 2022
Healthcare

Bioiberica unveils DAOgest and Dermial® for the first time at Vitafoods 2022.